The level of galectin-3 is correlated with tumor progression, and the concentration of circulating galectin-3 in the serum of cancer patients has been reported to be higher than that in healthy individuals (41), and a higher serum galectin-3 level was detected in patients with metastasis arising from prostate cancer (42). Here, LGALS3 is linked to neoplasm.